BIOPHARM FORWARD ApS: Financial statements 2019
CVR: 32438784
Source: annual report 2019, Danish Business Authority
26/08/2018 – 25/08/2019
BIOPHARM FORWARD ApS (CVR 32438784) has filed annual accounts for 2019. In 2019, the company reported a gross profit of DKK 291,460 and a net result of DKK 201,331 compared with DKK -1,877 the year before. Equity in the 2019 report amounted to DKK 171,229. The solvency ratio was 40.9%.
- Gross Profit
- DKK 291,460
- Profit/Loss
- DKK 201,331
- Equity
- DKK 171,229
- Total Assets
- DKK 418,181
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2019 | - | 291 t. | 201 t. | 171 t. | 0 |
| 2018 | - | -2 t. | -2 t. | -30 t. | - |
| 2017 | - | -2 t. | -2 t. | -28 t. | - |
| 2016 | - | -1 t. | -1 t. | -26 t. | - |
| 2015 | - | -2 t. | -2 t. | -25 t. | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
As of February 25, 2019, Jonas Hink is registered as director of BIOPHARM FORWARD ApS.
As of February 25, 2019, Bodil Elisabeth Fransiska Ørkild has stepped down as director of BIOPHARM FORWARD ApS.
About BIOPHARM FORWARD ApS
BIOPHARM FORWARD ApS is a Danish company of the type Anpartsselskab based in Espergærde, founded in 2009. The company is registered under the industry Andre liberale, videnskabelige og tekniske tjenesteydelser i.a.n.. The management consists of Jonas Hink. The company is owned by Jonas Hink. The company has 1 employee (2025). In 2025, the company reported a gross profit of DKK 997,234 and a net result of DKK 243,660 compared with DKK 385,061 the year before. Equity in the 2025 report amounted to DKK 1,741,315.